All In Biotech

Drug Trial Radar · NCT07634198

A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

A Randomized, Double-Blind, Positive-Controlled, Parallel-Group, Multicenter Phase III Clinical Trial to Compare Efficacy and Safety of YK-1169 Versus Ceftazidime-Avibactam for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

590

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Apr 1, 2028

Study completion Apr 1, 2028

Sponsor

Sponsor type
Industry
First posted
Jun 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the all-cause mortality rate at Day 28 in the YK-1169 group versus the ceftazidime-avibatan injection group in the mITT population.

Conditions

  • Hospital-acquired Bacterial Pneumonia (HABP)
  • Ventilator-associated Bacterial Pneumonia (VABP)

Interventions

  • YK-1169Drug

    Dissolve 2.5 g of YK-1169 in 0.9% saline solution to a total volume of 100 mL, and administer by intravenous infusion at a constant rate over 120 minutes (±15 min), once every 8 hours (±30 min); the total duration of treatment is 7 to 14 days.

  • Ceftazidime-avibactam InjectionDrug

    Dissolve 2.5 g of ceftazidime-avibactam in 0.9% saline solution to a total volume of 100 mL, and administer by intravenous infusion at a constant rate over 120 minutes (±15 min), once every 8 hours (±30 min); the total duration of treatment is 7 to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with all-cause mortality in the mITT population at Day 28Time frame: Day 28

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.